Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Summary of Significant Accounting Policies (Details Textual)

v3.10.0.1
Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2017
Mar. 31, 2018
Sep. 30, 2017
Dec. 31, 2019
Sep. 30, 2018
Jan. 01, 2018
Dec. 31, 2017
Notes Payable, Fair Value Disclosure         $ 2,200,000   $ 2,400,000
Notes Payable, Current, Total         2,164,330   2,353,639
Derivative Liability, Total         63,000   63,000
Deferred Revenue           $ 726,061  
Cumulative Effect of New Accounting Principle in Period of Adoption             (700,000)
Accounting Standards Update 2014-09 [Member] | Sayre Pharmaceuticals [Member]              
Deferred Revenue           700,000  
Cumulative Effect of New Accounting Principle in Period of Adoption           $ 700,000  
Accounting Standards Update 2016-18 [Member] | Fiscal Year 2016 [Member]              
Prior Period Reclassification Adjustment   $ 5,000,000          
Accounting Standards Update 2016-02 [Member] | Scenario, Forecast [Member]              
Operating Lease, Right-of-Use Asset       $ 300,000      
Operating Lease, Liability, Total       $ 300,000      
Series NN Warrants [Member]              
Class of Warrant or Right, Term 5 years            
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 1.50            
Series NN Warrants [Member] | Cardinal Health 414 [Member]              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 10,000,000            
Class of Warrant or Right, Grants in Period, Estimated Fair Value     $ 3,300,000        
Series NN Warrants [Member] | UCSD [Member]              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 1,000,000   1,000,000        
Class of Warrant or Right, Grants in Period, Estimated Fair Value     $ 334,000        
Former Executive [Member]              
Accounts Payable, Disputed         $ 96,000   $ 96,000